SCHEMBL5822903

SCHEMBL5822903

CC(C)(Oc1cccc(Cl)c1Cl)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ PPARA Q07869 9/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PPARG P37231 5/20 0.44
▸ FABP2 P12104 1/20 0.44
▸ SLC22A12 Q96S37 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MRGPRX4 Q96LA9 1/20 0.42
▸ HTR1D P28221 2/20 0.42
▸ PPARD Q03181 4/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1046455 0.86 ALDH1A1 (0.60) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL11939834 0.85 ALDH1A1 (0.55) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL29195871 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL10907463 0.82 KDM4E (0.53) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL10715008 0.81 PPARA (0.41) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL5800645 0.80 PPARA (0.55) ALDH1A1KDM4EHSD17B10PPARAKMT2A
SCHEMBL12804549 0.80 PPARA (0.56) ALDH1A1PPARAKMT2ACYP1A2CYP3A4
SCHEMBL24252065 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EKMT2AMEN1CYP2C19
SCHEMBL11751450 0.78 KMT2A (0.40) ALDH1A1KDM4EKMT2AMEN1CYP2C19
SCHEMBL11823888 0.77 KDM4E (0.55) ALDH1A1KDM4EHSD17B10PPARAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006058199-A1 METHODS OF MODULATING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND PHARMACEUTICAL FORMULATIONS FOR THE SAME FAZIX CORPORATION (US) 2006-06-01 — — WO disclosed
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same FAZIX CORPORATION. 2006-05-25 — — US disclosed
US-4826861-A MEDICAL BACTERICIDES OR FUNGICIDES ALBERT ROLAND, S.A. (FR) 1989-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same HDLBP, LDLR, CETP ALDH1A1 3198/4885KDM4E 2223/4885HSD17B10 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback